Clinical microbiology and microbiota medicine (CliMic)
Our main focus is chronic infectious, inflammatory and metabolic diseases, including cardiovascular disease.
The gut microbiome comprises 300-500 times the gene count compared to the human genome, and is an immunologically and metabolically active organ that shows considerable variation between individuals.
We apply cross-sectional and longitudinal study designs as well as randomized controlled trials (RCTs), including pilot studies of probiotics in HIV infection, and the first adequately powered RCT targeting the gut microbiome in heart failure.
Other planned studies include the gut microbiota as a stratification tool for tailoring biological treatment in various inflammatory disorders, and for improving diagnostics of comorbidites in HIV-infected individuals.